We recently compiled a list of the Jim Cramer Discussed These 12 Stocks Amidst The DeepSeek AI Selloff. In this article, we ...
The company disclosed preliminary results in mid January, but it left out important metrics such as earnings per share for the fourth quarter.
That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...
SAN FRANCISCO — Eli Lilly CEO Dave Ricks on Tuesday said he believed the company could find “significant common cause” with the incoming Trump administration, including on issues around ...
Eli Lilly forecasts $45 billion in 2024 revenue ... During the conference, David Ricks outlined two reasons for the guidance update: The diabetes GLP market, in December, outperforms the rest ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the ...
The latest declines in Eli Lilly's stock price occurred in response to management's presentation at the annual JPMorgan Healthcare conference. On Jan. 14, CEO David Ricks told investors that ...
Eli Lilly Chief Corporate Brand Officer Lina Polimeni on how the brand differentiates itself in the crowded pharma market, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback